CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Tom Schalekamp; Gerard J. J. Boink; Loes E. Visser; Bruno H. Ch Stricker; Anthonius de Boer; Olaf H. Klungel

doi:10.1016/j.clpt.2006.03.008

CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?

Tom Schalekamp
, Gerard J. J. Boink
, Loes E. Visser
, Bruno H. Ch Stricker
, Anthonius de Boer
, Olaf H. Klungel

Research output: Contribution to journal › Editorial › Academic › peer-review

Original language	English
Pages (from-to)	511-520
Journal	Clinical pharmacology and therapeutics
Volume	79
Issue number	6
DOIs	https://doi.org/10.1016/j.clpt.2006.03.008
Publication status	Published - 2006

Access to Document

10.1016/j.clpt.2006.03.008

Cite this

@article{7a59570263be447280ec4af7981d7899,

title = "CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring?",

author = "Tom Schalekamp and Boink, \{Gerard J. J.\} and Visser, \{Loes E.\} and Stricker, \{Bruno H. Ch\} and \{de Boer\}, Anthonius and Klungel, \{Olaf H.\}",

year = "2006",

doi = "10.1016/j.clpt.2006.03.008",

language = "English",

volume = "79",

pages = "511--520",

journal = "Clinical pharmacology and therapeutics",

issn = "0009-9236",